Panbela Therapeutics (STU:X70) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:X70 Panbela Therapeutics Inc STU:X70
29 GF Score
Price €119.40
View Full Analysis

What is Panbela Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

STU:X70
29GF Score
Panbela Therapeutics Inc STU:X70
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Panbela Therapeutics Business Description

Address 712 Vista Boulevard, Suite 305, Waconia, MN, USA, 55387
Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.
29GF Score

Get the complete analysis for STU:X70

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€119.40
Price